147 related articles for article (PubMed ID: 28960391)
1. Multicentre clinical evaluation of the new highly sensitive Elecsys® thyroglobulin II assay in patients with differentiated thyroid carcinoma.
Trimboli P; Imperiali M; Piccardo A; CampennÌ A; Giordani I; Ruggeri RM; Baldari S; Orlandi F; Giovanella L
Clin Endocrinol (Oxf); 2018 Feb; 88(2):295-302. PubMed ID: 28960391
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
[TBL] [Abstract][Full Text] [Related]
3. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
Spencer C; Fatemi S; Singer P; Nicoloff J; Lopresti J
Thyroid; 2010 Jun; 20(6):587-95. PubMed ID: 20470203
[TBL] [Abstract][Full Text] [Related]
4. Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference.
Crane MS; Strachan MW; Toft AD; Beckett GJ
Ann Clin Biochem; 2013 Sep; 50(Pt 5):421-32. PubMed ID: 23847033
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the highly sensitive Roche thyroglobulin II assay and establishment of a reference limit for thyroglobulin-negative patient samples.
Rotteveel-de Groot DM; Ross HA; Janssen MJR; Netea-Maier RT; Oosting JD; Sweep FCGJ; van Herwaarden AE
Pract Lab Med; 2016 Aug; 5():6-13. PubMed ID: 28856198
[TBL] [Abstract][Full Text] [Related]
6. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission.
Fugazzola L; Mihalich A; Persani L; Cerutti N; Reina M; Bonomi M; Ponti E; Mannavola D; Giammona E; Vannucchi G; di Blasio AM; Beck-Peccoz P
J Clin Endocrinol Metab; 2002 Jul; 87(7):3201-8. PubMed ID: 12107225
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
[TBL] [Abstract][Full Text] [Related]
8. Multi-center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay.
Evans C; Lotz J; Bhandari M; Hellier RT; Wang XY; Lott R; Lackner KJ; Müller R; Kulasingam V
J Clin Lab Anal; 2022 Sep; 36(9):e24595. PubMed ID: 35837992
[TBL] [Abstract][Full Text] [Related]
9. Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor® Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma.
Giovanella L; Verburg FA; Trimboli P; Imperiali M; Keller F; Ceriani L
Clin Chem Lab Med; 2019 Jul; 57(8):1185-1191. PubMed ID: 30835250
[TBL] [Abstract][Full Text] [Related]
10. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
11. High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas.
Trimboli P; Zilioli V; Imperiali M; Ceriani L; Giovanella L
Eur J Endocrinol; 2017 May; 176(5):497-504. PubMed ID: 28137736
[TBL] [Abstract][Full Text] [Related]
12. Comparison between a new thyroglobulin assay with the well-established Beckman Access immunoassay: A preliminary report.
Cennamo M; La Civita E; Curci A; Liotti A; Braschi U; Terracciano D
J Clin Lab Anal; 2021 Feb; 35(2):e23589. PubMed ID: 32951246
[TBL] [Abstract][Full Text] [Related]
13. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
[TBL] [Abstract][Full Text] [Related]
14. Thyroglobulin and thyroglobulin antibodies: assay-dependent management consequences in patients with differentiated thyroid carcinoma.
van Kinschot CMJ; Peeters RP; van den Berg SAA; Verburg FA; van Noord C; van Ginhoven TM; Visser WE
Clin Chem Lab Med; 2022 Apr; 60(5):756-765. PubMed ID: 35108464
[TBL] [Abstract][Full Text] [Related]
15. Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma.
González C; Aulinas A; Colom C; Tundidor D; Mendoza L; Corcoy R; Mato E; Alcántara V; Urgell Rull E; de Leiva A
Clin Endocrinol (Oxf); 2014 Feb; 80(2):301-6. PubMed ID: 23826916
[TBL] [Abstract][Full Text] [Related]
16. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.
Montella L; Caraglia M; Abbruzzese A; Soricelli A; Prete SD; Squame G; Salvatore M
Exp Mol Med; 2004 Jun; 36(3):268-73. PubMed ID: 15272239
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
[TBL] [Abstract][Full Text] [Related]
18. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma.
Deza S; Maroto J; Tellechea O; Orbegozo N; Merino J; Galofré JC; Alegre E; González Á
Clin Chim Acta; 2023 Aug; 548():117502. PubMed ID: 37516333
[TBL] [Abstract][Full Text] [Related]
20. The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer.
Kowalska A; Pałyga I; Gąsior-Perczak D; Walczyk A; Trybek T; Słuszniak A; Mężyk R; Góźdź S
PLoS One; 2015; 10(7):e0133852. PubMed ID: 26230494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
